Dr. David Erritzoe to provide guidance on psychopharmacological research
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College's Center for Psychedelic Research, has been appointed to Entheon's Advisory Board.
Dr. Erritzoe has significant experience in psychiatry, neuropsychopharmacology and psychedelic research. He is currently leading a new National Health Service (BHS) based research clinic, the CIPPRes Clinic, a collaborative, multidisciplinary research initiative between the Imperial College in London and the St. Charles Hospital.
Dr. Erritzoe conducts research using brain imaging techniques including PET and MRI scans and has conducted research into the neurobiology of addictions and depression.
"We continue to research the links between dopamine neurotransmitters and addictions, including the role that functional imaging studies can play in looking at various substance use disorders," said Dr. Erritzoe. 'As we continue to advance our knowledge in this area, I look forward to working with Entheon as they work to clinically advance DMT."
"Dr. Erritzoe's extensive hands-on experience in the realm of clinical research and his focus on substance-use disorders is a significant addition for Entheon and its Advisory Board as we work to further develop DMT through regulatory channels," said Chief Executive Officer, Timothy Ko. "I would like to extend a warm welcome to David and look forward to the insight a researcher of his caliber brings to the Company."
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("DMT Products") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
About Dr. David Erritzoe
Dr. Erritzoe is Clinical Senior Lecturer in General Psychiatry in Centres for Neuropsychopharmacology and Psychedelic Research at Imperial College, London, and is Consultant Psychiatrist at St Charles Hospital, CNWL Mental Health NHS Foundation Trust. From early 2021 heading a new NHS-based research clinic at St Charles Hospital, the CIPPRes Clinic.
David was trained in PET imaging at Columbia University in New York and later undertook a PhD at University Hospital Rigshospitalet in Copenhagen and is qualified as a medical doctor from Copenhagen University Medical School.
On Behalf of the Board of Directors,
Timothy Ko, CEO
For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
https://entheonbiomedical.com/
For media inquiries, please contact Crystal Quast at:
Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
quast@bullseyecorporate.com
Cautionary Note on Forward-Looking Information
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the engagement and advisory services of Dr. David Erritzoe as " Advisor", the development of the Company's clinical program, and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise further capital and the Company's ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94316
